TX-COGNITIVE-SPACE
6.7.2021 15:02:10 CEST | Business Wire | Press release
Cognitive Space today announced it has been selected to participate in the Amazon Web Services (AWS) Space Accelerator , a business support program for startups seeking to use AWS to help solve the biggest challenges in the space industry. This opportunity will support Cognitive Space efforts to revolutionize satellite operations by bringing the power of artificial intelligence and machine learning to mission operations and collection planning. Cognitive Space provides New Space organizations with sophisticated tools for optimizing revenue and performance yield as their satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005120/en/
New for 2021, the four-week AWS Space Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support in collaboration with Seraphim, one of the world’s leading investment groups focused exclusively on the space industry, who will provide business development and investment guidance.
Cognitive Space will rely on AWS Cloud infrastructure for its own Space-focused software products - including licensed services, underlying platform architecture, development & test environments, and AI/ML training and processing workloads. Cognitive Space will take advantage of AWS services for scalability, cost-effectiveness, security, reliability, and global reach.
“Being one of the few startups accepted into the AWS Space Accelerator is a great honor and we appreciate the confidence AWS has placed in us,” said Scott Herman, CEO of Cognitive Space. “We’re very excited about the mentoring opportunity that the accelerator provides to startups like ours, and we look forward to working closely with AWS and Seraphim as we build our company.” Guy de Carufel, CTO of Cognitive Space, added “We depend on Amazon Web Services to provide high-reliability and scalable infrastructure for the satellite operations services we deliver to our customers and partners, and we are eager to learn more from the AWS experts during the accelerator.”
As one of 10 companies chosen for this opportunity out of a field of approximately 200 startups, Cognitive Space will receive up to $100,000 in AWS Activate credit, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors.
“AWS looks forward to collaborating with our finalists to advance their inspiring vision for transforming how we understand, operate in, and benefit from space,” said Clint Crosier, director of the Aerospace and Satellite business at AWS. “Congratulations to our finalists, who were selected from hundreds of impressive startups from across the global space industry. The cloud is uniquely suited to spur the success of space companies in so many ways, and we are excited to help these companies achieve their biggest goals.”
Proposals were judged on several factors including the innovative and unique nature of the project, the overall value the solution will bring to the space industry, the creative application of AWS to solve problems, and the team’s ability to deliver on its specific mission.
For more information on the AWS Space Accelerator, visit https://seraphim.vc/aws/accelerator/ .
About Cognitive Space
Cognitive Space is developing advanced automation systems for the space industry with a particular focus on the software management of satellite constellations, including mission management, collection planning, communication link management, and modeling & simulation of future capabilities.
Our early focus is on orchestrated collection management for the explosion of new remote sensing constellations - multi-phenomenology, large-fleet constellations of small satellite sensors that offer unprecedented facility monitoring, activity monitoring, and pattern-of-life analysis for national security and commercial organizations with a global monitoring mission.
Cognitive Space is developing an AI-driven solution for near real-time dynamic mission planning for Low Earth Orbit (LEO) Satellites. By 2030, research analysts predict 15-20x growth in deployed satellites in service, from 3000 in 2021 to ~50,000 satellites in orbit. Satellite constellations are increasingly being tasked by government and commercial consumers for use cases including communications, agriculture, environmental protection, meteorology, navigation, national defense, and myriad other commercial, military and governmental use cases.
The Cognitive Space satellite constellation management platform allows operators to reduce command and control lead time, reduce human errors and streamline satellite asset integration. For commercial operators this allows them to maximize service capacity, increase revenue and margin, and optimize performance yield. Cognitive Space’s platform is multi-purpose, serving the needs of the Federal Government, US Department of Defense and commercial enterprises.
More information about Cognitive Space can be found at http://www.cognitivespace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom